Drug Trial Radar · NCT07948811
A Study Evaluating the Antipyretic Efficacy and Safety of an Acetaminophen/Naproxen Sodium Fixed Combination in Subjects With Endotoxin-Induced Fever
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
292
Planned (sponsor's estimate)
Start
Oct 20, 2026
Primary completion
Oct 29, 2027
Study completion Oct 29, 2027
Sponsor
- Lead sponsor
- Kenvue Brands LLCIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the antipyretic efficacy of a single dose of a fixed combination of acetaminophen/naproxen sodium, compared with placebo.
Conditions
- Fever
Interventions
Acetaminophen 650 mg/Naproxen Sodium 220 mgDrug
The IP is to be taken as a single dose (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg) orally with 180 mL of room temperature water.
Placebo tabletDrug
The placebo is to be taken as a single dose (administered as two tablets of placebo) orally with 180 mL of room temperature water.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-weighted Sum of Temperature Differences (WSTD) from 0 to 8 hours (WSTD 0-8)Time frame: Baseline (0 hour) up to 8 hours
- Time-weighted Sum of Temperature Differences (WSTD) from 0 to 12 hours (WSTD 0-12)Time frame: Baseline (0 hour) up to 12 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
AMR Clinical - Knoxville Tennessee
Knoxville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.